ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025
Incidence of Fever Associated With Dexmedetomidine in Critically Ill Children.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the incidence of fever in critically ill pediatric patients receiving continuously infused dexmedetomidine.
methodsThis was a retrospective study of pediatric patients admitted to the pediatric or neonatal intensive care unit (PICU or NICU) between November 2017 and December 2021 who received dexmedetomidine. The primary endpoint was defined as a fever ≥38°C while receiving dexmedetomidine. Patient- and drug-specific characteristics between the fever and non-fever groups were compared to identify possible trends.
resultsA total of 151 patients were included, with a median age of 15.8 months (IQR, 2.9-48.1). Thirteen patients (8.6%) met the criteria for the primary endpoint, with a mean maximum temperature of 38.2°C ± 0.2°C. Median time of fever onset was 9.7 hours (IQR, 2.0-29.3) into their dexmedetomidine infusion with a median dose of 0.4 mcg/kg/hr (IQR, 0.2-0.6). Patients within the fever group were younger (1.7 months [IQR, 1.1-8.6] vs 17.3 months [IQR, 3.3-65.5], p = 0.0006), reached a higher maximum infusion rate (0.8 mcg/kg/hr [IQR, 0.6-0.9] vs 0.6 mcg/kg/hr [IQR, 0.4-0.8], p = 0.0343), and received dexmedetomidine for longer durations (83.2 hours [IQR, 64.2-128.3] vs 35.2 hours [IQR, 17.6-55.7], p < 0.0001) than the non-fever group.
conclusionsFever ≥38°C was observed in 8.6% of PICU and NICU patients receiving dexmedetomidine. Younger patients or those exposed to higher doses or longer durations of dexmedetomidine may be at increased risk. Prospective studies will be required to further validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.